Daiwa Securities Group’s Crescent Biopharma CBIO Stock Holding History

Daiwa Securities Group’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-3	Closed	-$1K	–	1270
2020 Q3	$1K	Hold	3	–	–	﹤0.01%	1164
2020 Q2	$1K	Hold	3	–	–	﹤0.01%	1187
2020 Q1	$1K	Hold	3	–	–	﹤0.01%	1190
2019 Q4	$1K	Hold	3	–	–	﹤0.01%	1185
2019 Q3	$1K	Hold	3	–	–	﹤0.01%	1151
2019 Q2	$3K	Hold	3	–	–	﹤0.01%	1130
2019 Q1	$3K	Buy	3 +1	+50%	+$1.15K	﹤0.01%	1106
2018 Q4	$2K	Hold	2	–	–	﹤0.01%	1105
2018 Q3	$3K	Hold	2	–	–	﹤0.01%	1105
2018 Q2	$3K	Hold	2	–	–	﹤0.01%	1124
2018 Q1	$3K	Buy	+2	New	+$4.16K	﹤0.01%	1103

Other funds holding CBIO

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Daiwa Securities Group's CBIO Position: Q4 2020 in Review

Daiwa Securities Group sold out of Crescent Biopharma (CBIO) in Q4 2020, closing a stake of 3 shares — an estimated $1K sold.

Daiwa Securities Group first reported a position in CBIO in Q1 2018 and held it in 11 quarters. The position peaked at $3K in Q2 2019. 89 funds tracked by Wall St. Rank hold CBIO as of Q4 2020.

Daiwa Securities Group reported no remaining Crescent Biopharma position as of Q4 2020 after selling out during the quarter.
Daiwa Securities Group sold 3 Crescent Biopharma shares in Q4 2020, an estimated $1K.
Daiwa Securities Group first reported a position in Crescent Biopharma in Q1 2018 and held it in 11 quarters.
Daiwa Securities Group's Crescent Biopharma position peaked at $3K in Q2 2019.
89 funds tracked by Wall St. Rank held Crescent Biopharma as of Q4 2020.

Based on Daiwa Securities Group's 13F filing for Q4 2020, filed 4 Feb 2021.